目的 分析艾沙康唑所致藥品不良反應的臨床特點，為臨床安全應用該藥提供參考。方法 檢索中國知網、萬方、維普、PubMed和Embase數據庫截至2024年8月收錄的艾沙康唑相關不良反應案例報道和病例系列分析，對涉及患者的一般資料、用藥情況、不良反應發(fā)生時間、主要臨床表現、治療及轉歸等信息進行描述性統(tǒng)計分析。結果 共納入文獻15篇，涉及患者26例，男女比例2.25∶1，患者中位年齡60（39，69）歲，以肺部侵襲性真菌病治療性用藥為主。不良反應發(fā)生中位時間為10（4.8，17.5）d，20例（76.92%）患者的不良反應發(fā)生在用藥1個月以內。26例患者共發(fā)生39例次不良反應，嚴重不良反應占比26.92%，主要為用藥所致的各種程度肝損傷；不良反應共累及11個系統(tǒng)器官（SOC），排名前3位的為神經系統(tǒng)、肝膽系統(tǒng)和各類實驗室檢查異常。新的不良反應（28.21%）分布于各SOC，暫未見明顯特征。24例患者經治療后好轉/痊愈，中位轉歸時間為7（2，10.25）d。結論 臨床在用藥時需掌握艾沙康唑致各系統(tǒng)不良反應的特點，根據其可能機制或流行病學信息，關注易發(fā)生不良反應的高危人群，以便及時處理用藥時遇到的風險。

Objective To analyze the clinical characteristics of adverse drug reactions caused by isavuconazole, and provide reference for the safe use of the drug in clinical practice. Methods Retrieve adverse drug reactions case reports and case series analysis related to isavuconazole from databases such as CNKI, Wanfang, VIP, PubMed, and Embase as of August 2024. Descriptive statistical analysis was conducted on patient general information, medication use, adverse drug reactions occurrence time, main clinical manifestations, treatment, and outcomes. Results A total of 15 articles were included in the study, involving 26 patients with a male to female ratio of 2.25∶1. The median age of the patients was 60 (39, 69) years old, and they mainly used therapeutic drugs for invasive fungal diseases of the lungs. The median time for adverse drug reactions occurrence was 10 (4.8, 17.5) d, and adverse reactions occurred within one month of medication in 20 patients (76.92%). A total of 39 adverse drug reactions occurred in 26 patients, with severe adverse reactions accounting for 26.92%, mainly due to various degrees of liver damage caused by medication. Adverse drug reactions affects a total of 11 systemic organs (SOC), with the top three being the nervous system, hepatobiliary system, and various laboratory abnormalities. The new adverse drug reactions (28.21%) is distributed among various SOC, and no obvious characteristics have been observed yet. 24 patients recovering/recovered after treatment, with a median transition time of 7 (2, 10.25) d. Conclusion In clinical practice, it is necessary to understand the characteristics of adverse drug reactions caused by isavuconazole in various systems, and based on its possible mechanisms or epidemiological information, pay attention to high-risk populations that are prone to adverse drug reactions, in order to timely handle the risks encountered during medication.

R978.5